SEC Form 4 · accession 0001209191-16-129177
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel D Colella
Director · 10% Owner
Period of report
Jun 20, 2016
Accepted (ET)
Jun 22, 2016 · 1:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 20, 2016 | P | 3,435 | $13.9796 | A | 3,435 | D | |
| Common StockF2 | Jun 20, 2016 | P | 3,343 | $13.7043 | A | 6,778 | D | |
| Common StockF3 | Jun 21, 2016 | P | 13,222 | $13.6223 | A | 20,000 | D | |
| Common StockF4 | Jun 21, 2016 | P | 4,600 | $13.7583 | A | 24,600 | D | |
| Common StockF5 | Jun 21, 2016 | P | 504 | $13.6523 | A | 25,104 | D | |
| Common StockF6 | Jun 21, 2016 | P | 400 | $13.7078 | A | 25,504 | D | |
| Common StockF7 | holding | — | — | — | 3,511,670 | I | See Footnote | |
| Common StockF8 | holding | — | — | — | 20,739 | I | See Footnote | |
| Common StockF9 | holding | — | — | — | 388,683 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The weighted average sale price for the transaction reported was $13.9796206, and the range of prices were between $13.965 and $14.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F2The weighted average sale price for the transaction reported was $13.7043, and the range of prices were between $13.34 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F3The weighted average sale price for the transaction reported was $13.6223, and the range of prices were between $13.41 and $14.175. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F4The weighted average sale price for the transaction reported was $13.7583, and the range of prices were between $13.65 and $13.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F5The weighted average sale price for the transaction reported was $13.6523, and the range of prices were between $13.62 and $13.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F6The weighted average sale price for the transaction reported was $13.7078, and the range of prices were between $13.701546 and $13.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F7The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
- F8The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
- F9The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.